BACKGROUND: A prospective study was undertaken to evaluate a policy of selective, single-modality elective neck treatment in T1-2, node-negative oral tongue squamous cell carcinoma. METHODS: Where the primary tumor showed 1 of the 4 key pathological criteria (greater than 7 mm of muscle invasion, less than 5 mm of resection margin, perineural or lymphovascular invasion), radiotherapy was delivered to the primary site and the at-risk undissected neck. Otherwise patients underwent ipsilateral neck dissection within 4 weeks of initial resection. Prospective quality of life assessments were performed. RESULTS: The study was closed after accrual of 25 patients, because the high locoregional recurrence rate met early stopping criteria. With a median follow-up of 3.4 years, the locoregional recurrence rate was 23%. The 4-year overall and disease-free survival rates were 71% and 64%, respectively. CONCLUSION: The poor disease-free survival reflects the need for better prognostic markers and more aggressive treatment in these patients. Copyright 2009 Wiley Periodicals, Inc.
BACKGROUND: A prospective study was undertaken to evaluate a policy of selective, single-modality elective neck treatment in T1-2, node-negative oral tongue squamous cell carcinoma. METHODS: Where the primary tumor showed 1 of the 4 key pathological criteria (greater than 7 mm of muscle invasion, less than 5 mm of resection margin, perineural or lymphovascular invasion), radiotherapy was delivered to the primary site and the at-risk undissected neck. Otherwise patients underwent ipsilateral neck dissection within 4 weeks of initial resection. Prospective quality of life assessments were performed. RESULTS: The study was closed after accrual of 25 patients, because the high locoregional recurrence rate met early stopping criteria. With a median follow-up of 3.4 years, the locoregional recurrence rate was 23%. The 4-year overall and disease-free survival rates were 71% and 64%, respectively. CONCLUSION: The poor disease-free survival reflects the need for better prognostic markers and more aggressive treatment in these patients. Copyright 2009 Wiley Periodicals, Inc.
Authors: Ardalan Ebrahimi; Ziv Gil; Moran Amit; Tzu-Chen Yen; Chun-Ta Liao; Pankaj Chaturvedi; Jai Prakash Agarwal; Luiz P Kowalski; Hugo F Köhler; Matthias Kreppel; Claudio R Cernea; Jason Brandao; Gideon Bachar; Andrea Bolzoni Villaret; Dan M Fliss; Eran Fridman; Kevin Thomas Robbins; Jatin P Shah; Snehal G Patel; Jonathan R Clark Journal: Head Neck Date: 2019-02-24 Impact factor: 3.147
Authors: Shlomo A Koyfman; Nofisat Ismaila; Doug Crook; Anil D'Cruz; Cristina P Rodriguez; David J Sher; Damian Silbermins; Erich M Sturgis; Terance T Tsue; Jared Weiss; Sue S Yom; F Christopher Holsinger Journal: J Clin Oncol Date: 2019-02-27 Impact factor: 44.544
Authors: Yufeng Li; Shuting Bai; William Carroll; Dan Dayan; Joseph C Dort; Keith Heller; George Jour; Harold Lau; Carla Penner; Michael Prystowsky; Eben Rosenthal; Nicolas F Schlecht; Richard V Smith; Mark Urken; Marilena Vered; Beverly Wang; Bruce Wenig; Abdissa Negassa; Margaret Brandwein-Gensler Journal: Head Neck Pathol Date: 2012-12-19
Authors: Baris Karakullukcu; Sharon D Stoker; Anne P E Wildeman; Marcel P Copper; Maarten A Wildeman; I Bing Tan Journal: Eur Arch Otorhinolaryngol Date: 2012-07-07 Impact factor: 2.503
Authors: Annette M Lim; Nicholas C Wong; Ruth Pidsley; Elena Zotenko; June Corry; Alexander Dobrovic; Susan J Clark; Danny Rischin; Benjamin Solomon Journal: Clin Epigenetics Date: 2016-07-18 Impact factor: 6.551
Authors: Jeffrey C Liu; Dennis S Sopka; Ranee Mehra; Miriam N Lango; Christopher Fundakowski; John A Ridge; Thomas J Galloway Journal: World J Otorhinolaryngol Head Neck Surg Date: 2016-05-05